Neurodegenerative diseases, such as Parkinson’s and Alzheimer’s, are becoming an increasingly serious challenge for modern medicine because of the significant increase in incidence and the narrow range of effective therapeutic strategies. In recent years, the kynurenine pathway, which is one of the main pathways of tryptophan metabolism, responsible for the synthesis of products that act oppositely in the CNS including neurotoxic (quinolinic acid) and neuroprotective products, has gained increasing recognition as a potential therapeutic target. Abnormalities in the production of these metabolites, causing a disruption of homeostasis in the CNS, often lead to the development of inflammation, which can cause oxidative stress or neuronal death. This paper aims to discuss strategies useful in modulation of the kynurenine pathway, based on increasing the production of neuroprotective metabolites and reducing the synthesis of neurotoxic compounds, as well as to outline the progress in preclinical and clinical studies and the challenges encountered in these studies, among others, in the search for new KP inhibitors. The pharmacological (IDO and KMO inhibitors) and non-pharmacological (physical activity, diet) strategies are discussed, as well as new approaches from combination and targeted therapies. Together with the results of preclinical studies, they demonstrate the high utility of this target in the treatment of neurodegeneration. Despite its promising activity, further key studies are needed to fully understand the mechanisms involved in metabolism, which may translate into increased efficacy of developed therapies in the future.
Unfavorable epidemiological forecasts indicating a significant increase in cancer incidence and mortality, as well as limitations of traditional cancer treatment methods, prompt the search for new, more effective therapeutic strategies. In response to the difficulties in treating cancer resulting from the significant heterogeneity of the tumor microenvironment and the presence of hypoxic and necrotic zones, anaerobic bacteria from the Clostridiaceae family, particularly those of the Clostridium genus, are attracting increasing interest. These bacteria can selectively grow in hypoxic areas of tumors while showing no affinity for healthy tissues. An additional advantage of these bacteria is their ability to produce toxins and enzymes that enable the lysis of cancer cells and activate the immune response. One of the most promising and distinctive strains is Clostridium novyi-NT, which lacks virulence factors and, in studies, has been shown to induce a strong cytolytic response. Modern genetic engineering has enabled the modification of Clostridiaceae bacteria to express enzymes that activate prodrugs, thereby significantly reducing systemic toxicity while targeting tumor tissue. Combining Clostridiaceae spore therapy with conventional treatments, such as chemotherapy, radiotherapy, or immunotherapy, significantly enhances their effectiveness, resulting in a highly beneficial synergistic therapeutic effect. The purpose of this review is to discuss the role and potential of Clostridiaceae bacteria in innovative anticancer therapies.